Navigation Links
Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
Date:5/23/2009

Boston-based biotech firm Replikins Ltd. (www.replikins.com) last week analyzed the most recent peptide genomic sequence data available and determined that the infectivity of the H1N1 virus will increase markedly, while its lethality will remain relatively low for the immediate future. The company's quantitative analysis of the most recent sequence data available on PubMed, a standard scientific repository for published papers, showed an increase of 46% in the Replikin Count* over the past five months.

Boston, MA (PRWEB) May 23, 2009 -- Amid all the speculation over what course the Swine Flu epidemic will take, Boston-based biotech firm Replikins Ltd. (www.replikins.com) last week analyzed the most recent peptide genomic sequence data available and determined that the infectivity of the H1N1 virus will increase markedly, while its lethality will remain relatively low for the immediate future.


The company's quantitative analysis of the most recent sequence data available on PubMed, a standard scientific repository for published papers, showed an increase of 46% in the Replikin Count* over the past five months. This points to a marked increase in infectivity in humans. At the same time, while the total number of replikins has gone up significantly, their composition appears to have changed in a way that makes them more closely resemble their counterparts in earlier pandemics.

The firm, which had predicted a year ago the likelihood of the current H1N1 outbreak, used its proprietary FluForecast™ software program to make these determinations. "The dual differentiation of these properties may provide advance warning of the future course of H1N1," noted Samuel Bogoch MD PhD, chairman and founder of Replikins Ltd. "Our understanding of the protein chemistry of rapid replication enables us to develop synthetic vaccines specifically tailored to destroy or restrict replication of the targeted virus strains prior to an outbreak."

Earlier this month, Replikins announced that it had succeeded in synthesizing the first H1N1 influenza vaccine, which is now ready for testing. It used the same approach to produce a peptide H5N1 (avian flu) vaccine that successfully blocked low path H5N1. It has not previously been possible to correlate virus structures with a virus outbreak or cessation of outbreak, let alone to predict six to 12 months ahead of the outbreak or its cessation. In 2001, Drs. Samuel and Elenore Bogoch first demonstrated this correlation retrospectively for whole-organism replikin counts in outbreaks and pandemics of the common influenza strains over the past century.

About Replikins Ltd.
Replikins, Ltd. (www.replikins.com), a Boston-based biotech company, develops and markets novel forecasting tools and synthetic vaccines to fight virulent rapidly replicating diseases including bird flu, malaria, and HIV. The company's predictive products and vaccines in development are based upon the company's discovery of Replikins, a new group of peptides related to the rapid replication function in viral and other diseases. The company has designed unique products to predict the emergence of virulent strains of particular diseases (FluForecast™) and is designing synthetic vaccines specifically tailored to combat a given strain and against shared properties of several strains (Syntope™ vaccines). The company is partnering with governments and the private sector in providing predictive tools and vaccines in furtherance of the public health initiative to prevent and combat epidemics.

*The company's vaccines and predictive tools are based on the company's discovery of a new group of peptides related to rapid replication called Replikins, whose increase in concentration in virus or other organism proteins (Replikin Count™ = number of replikins per 100 amino acids) is associated with rapid replication.

# # #

Read the full story at http://www.prweb.com/releases/Replikins/H1N1/prweb2457374.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Neogen Named Supplier of Chr. Hansen Probiotics for Swine and Poultry
2. Biotechnology Company Provided Advance Warning of Mexican H1N1 "Swine Flu" Virus Outbreak
3. Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 Swine Flu Virus Outbreak
4. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
5. Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
6. Medicago initiates work on Swine Flu strain
7. MMR Offers Free Surgical Masks to Call Attention to Importance of Personal Health Records in Preparing for Possible Swine Flu Pandemic
8. Swine Flu a Reminder: Using Hand Sanitizers Like Remi-D Helps Fight Infection
9. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
10. H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide
11. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
(Date:3/24/2017)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), ... , today announced that its board of directors has amended its ... from March 27, 2017 to March 27, 2018. The amendment was not ... Biotech Ltd. ... Sinovac Biotech Ltd. is a China -based ...
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the ... corporate cooking challenges for companies around the world, such as Illumina, HP and Qualcomm, and ... reason for its increasing popularity is due to its new team building format, a way ...
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
(Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
Breaking Biology News(10 mins):